Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Nanosphere

Nanosphere
1999 FOUNDED
M&A STATUS
101-200 EMPLOYEES
M&A LATEST DEAL TYPE
$102M LATEST DEAL AMOUNT
Description

molecular diagnostic tests. The company engages in research and development of diagnostic test platform that helps in disease detection, optimal patient treatment and improved healthcare economics.

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Decision/Risk Analysis
Other Industries
Social/Platform Software
Acquirer
Primary Office
  • 4088 Commercial Avenue
  • Northbrook, IL 60062
  • United States

+1 (847) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Nanosphere’s full profile, request a free trial.

Nanosphere Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 30-Jun-2016 $102M 00000 00000 Completed Generating Revenue
9. PIPE 11-May-2015 00.00 00000 Completed Generating Revenue
8. Debt - General 07-May-2015 0000 00000 Completed Generating Revenue
7. PIPE 19-Jul-2012 0000 00000 Completed Generating Revenue
6. IPO 01-Nov-2007 0000 00000 00000 Completed Generating Revenue
5. Later Stage VC (Series D) 26-Apr-2006 0000 00000 00000 Completed Generating Revenue
4. Later Stage VC (Series C2) 14-Oct-2004 0000 000.00 000.00 Completed Startup
3. Later Stage VC (Series C) 26-Nov-2002 0000 000.00 000.00 Completed Startup
2. Early Stage VC (Series B) $9M $12.4M 000.00 Completed Startup
1. Early Stage VC (Series A) 14-Jan-2000 $3.42M $3.42M 000.00 Completed Product Development
To view this company’s complete deal history including valuation and funding, request access »

Nanosphere Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series D 000,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series C2 000,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series C 10,066,673 $0.010000 8% $0.6 $0.6 1x $0.6 2.24%
Series B 17,007 $0.010000 8% $2.21 $2.21
To view this company’s complete Cap Table, request access »

Nanosphere Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Congenica Venture Capital-Backed Cambridge, United Kingdom 00 000.00 00000000000 000.00
00000000 000000000 Angel-Backed Westminster, CO 00.00 0000000000 00.00
0000000000 0000000 Private Equity-Backed Vancouver, Canada 0000000000
To view this company’s complete list of competitors, request access »

Nanosphere Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Allen & Company Investment Bank Minority 000 0000 000000 0
Bain Capital Ventures Venture Capital Minority 000 0000 000000 0
Lurie Investment Fund Corporate Venture Capital Minority 000 0000 000000 0
NGEN Partners Venture Capital Minority 000 0000 000000 0
Oxford Finance Lender/Debt Provider 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Nanosphere Executive Team (13)

Name Title Board
Seat
Contact
Info
Kenneth Bahk Ph.D Chief Strategy Officer
Farzana Moinuddin Chief Accounting Officer
Zachary Crowther Director, Marketing
Jim Hully Ph.D Director, Product Development
Teresa Raich Ph.D Senior Director, Clinical and Regulatory Affairs

5 Former Executives

You’re viewing 5 of 13 executives. Get the full list »

Nanosphere Board Members (8)

Name Representing Role Since Contact
Info
Erik Holmlin Ph.D Self Director 000 0000
Gene Cartwright Self Board Member 000 0000
Jeff Randall Self Board Member 000 0000
Sheli Rosenberg JD Nanosphere Chairman 000 0000

4 Former Board Members

You’re viewing 4 of 8 board members. Get the full list »